US FDA Approves Scenesse® for Genetic Disorder

  • Oct 09, 2019 AEDT
  • Team Kalkine

Clinuvel Pharmaceuticals Limited (ASX: CUV) has announced that US FDA has granted marketing approval to use SCENESSE® for the treatment of EPP (erythropoietic protoporphyria) patients in the US.

  • SCENESSE® is the first global systemic photoprotective drug for the treatment of patients with EPP;
  • SCENESSE® acts as a potent anti-oxidative and melanogenic agent providing pan dermal (total surface) photoprotection;
  • This genetic disorder causes absolute light intolerance and forces patients to lead an indoor or nocturnal existence.

At AEST 1:09 PM, the stock was trading at $39.490 per share, up by 40.584% from its previous close.


All pictures are copyright to their respective owner(s) does not claim ownership of any of the pictures displayed on this website unless stated otherwise. Some of the images used on this website are taken from the web and are believed to be in public domain. We have used reasonable efforts to accredit the source (public domain/CC0 status) to where it was found and indicated it below the image.


There is no investor left unperturbed with the ongoing trade conflicts between US-China and the devastating bushfire in Australia.

Are you wondering if the year 2020 might not have taken the right start? Dividend stocks could be the answer to that question.

As interest rates in Australia are already at record low levels, find out which dividend stocks are viewed as the most attractive investment opportunity in the current scenario in our report.

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK